| Methods |
Randomized |
| Participants |
Adults (mean 71)
46% CAP; 50% COPD exacerbation; 4% acute bronchitis
Hospitalized |
| Interventions |
Atypical: PO ciprofloxacin 500 mg X 2/d
Non‐atypical: PO amoxicillin 250 mg X 3/d |
| Outcomes |
Clinical and bacteriological:
complete success = clinical recovery, bacteriological eradication partial success = clinical improvement, bacteriological reduction/indeterminate unsuccessful = clinical failure, regardless of bacteriological response undetermined (assessment impossible) moderation = ?
|
| Notes |
Less than 50% CAP
Data analyzed only for pneumonia patients (given separately) |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not described |
| Allocation concealment (selection bias) |
Unclear risk |
Not described |
| Incomplete outcome data (attrition bias)
Mortality |
High risk |
48/52 patients evaluated |
| Incomplete outcome data (attrition bias)
Failure |
High risk |
48/52 patients evaluated |
| Selective reporting (reporting bias) |
Low risk |
Not identified |
| Other bias |
Unclear risk |
Sponsor? |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
None |
| Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
None |
